[go: up one dir, main page]

AU2001295531A1 - Antisense oligonucleotides against vanilloid receptor 1 - Google Patents

Antisense oligonucleotides against vanilloid receptor 1

Info

Publication number
AU2001295531A1
AU2001295531A1 AU2001295531A AU9553101A AU2001295531A1 AU 2001295531 A1 AU2001295531 A1 AU 2001295531A1 AU 2001295531 A AU2001295531 A AU 2001295531A AU 9553101 A AU9553101 A AU 9553101A AU 2001295531 A1 AU2001295531 A1 AU 2001295531A1
Authority
AU
Australia
Prior art keywords
antisense oligonucleotides
vanilloid receptor
oligonucleotides against
against vanilloid
nucleotide constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295531A
Inventor
Volker A. Erdmann
Jens Kurreck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000143674 external-priority patent/DE10043674A1/en
Priority claimed from DE10043702A external-priority patent/DE10043702A1/en
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2001295531A1 publication Critical patent/AU2001295531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.
AU2001295531A 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1 Abandoned AU2001295531A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10043674.9 2000-09-02
DE2000143674 DE10043674A1 (en) 2000-09-02 2000-09-02 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
DE10043702.8 2000-09-04
DE10043702A DE10043702A1 (en) 2000-09-04 2000-09-04 New antisense oligonucleotides and ribozymes, useful for treating e.g. pain and for diagnosis, are directed against mRNA for vanilloid-family receptors
PCT/EP2001/010081 WO2002018407A2 (en) 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1

Publications (1)

Publication Number Publication Date
AU2001295531A1 true AU2001295531A1 (en) 2002-03-13

Family

ID=26006931

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295531A Abandoned AU2001295531A1 (en) 2000-09-02 2001-08-31 Antisense oligonucleotides against vanilloid receptor 1

Country Status (13)

Country Link
US (2) US7662948B2 (en)
EP (1) EP1313768B1 (en)
JP (1) JP2004507263A (en)
AT (1) ATE385505T1 (en)
AU (1) AU2001295531A1 (en)
CA (1) CA2420656A1 (en)
DE (1) DE50113568D1 (en)
ES (1) ES2300366T3 (en)
HU (1) HUP0301805A3 (en)
MX (1) MXPA03001627A (en)
NZ (1) NZ524894A (en)
PL (1) PL366039A1 (en)
WO (1) WO2002018407A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105044A1 (en) * 2001-10-17 2003-06-05 Isis Pharmaceuticals Inc. Antisense modulation of matrix metalloproteinase 1 expression
EP1501930A2 (en) 2002-04-05 2005-02-02 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
DE10322662A1 (en) * 2002-11-06 2004-10-07 Grünenthal GmbH New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability
DE10257421A1 (en) * 2002-12-09 2004-07-08 Grünenthal GmbH Regulatory elements in the 5 'region of the VR1 gene
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
US7480382B2 (en) * 2003-09-30 2009-01-20 Microsoft Corporation Image file container
NZ555644A (en) * 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
CA2745811C (en) 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN102341498B (en) 2008-12-04 2017-12-19 库尔纳公司 Natural antisense transcripton by suppressing VEGF (VEGF) treats the related diseases of VEGF
ES2629630T3 (en) * 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
CA2752237C (en) 2009-02-12 2020-03-24 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2010107733A2 (en) 2009-03-16 2010-09-23 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
JP5904935B2 (en) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1)
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
CN106237345A (en) 2009-05-06 2016-12-21 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
CN102575251B (en) 2009-05-18 2018-12-04 库尔纳公司 The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
EP2432882B1 (en) 2009-05-22 2019-12-25 CuRNA, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
JP5960049B2 (en) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes
WO2010148065A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6073133B2 (en) 2009-06-24 2017-02-01 クルナ・インコーポレーテッド Treatment of TNFR2-related diseases by suppression of natural antisense transcripts against tumor necrosis factor receptor 2 (TNFR2)
ES2583691T3 (en) 2009-06-26 2016-09-21 Curna, Inc. Treatment of diseases related to a Down syndrome gene by inhibiting a natural antisense transcript to a Down syndrome gene
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US8572084B2 (en) * 2009-07-28 2013-10-29 Fti Consulting, Inc. System and method for displaying relationships between electronically stored information to provide classification suggestions via nearest neighbor
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
WO2011019815A2 (en) 2009-08-11 2011-02-17 Curna, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8791087B2 (en) 2009-08-21 2014-07-29 Curna, Inc. Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
CA2775111C (en) 2009-09-25 2019-12-31 Opko Curna, Llc Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
CA2782375C (en) 2009-12-23 2023-10-31 Opko Curna, Llc Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
KR101838305B1 (en) 2009-12-29 2018-03-13 큐알엔에이, 인크. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2011082281A2 (en) 2009-12-31 2011-07-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
CA2785832A1 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
JP5963680B2 (en) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド Treatment of pancreatic developmental gene diseases by inhibition of natural antisense transcripts against pancreatic developmental genes
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
RU2608496C2 (en) 2010-02-22 2017-01-18 Курна, Инк. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
ES2657969T3 (en) 2010-04-02 2018-03-07 Curna, Inc. Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3
CA2795281A1 (en) 2010-04-09 2011-10-13 Curna, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
JP2013525483A (en) 2010-05-03 2013-06-20 カッパーアールエヌエー，インコーポレイテッド Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcripts against sirtuin (SIRT)
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
ES2664572T3 (en) 2010-05-26 2018-04-20 Curna, Inc. Treatment of diseases related to the atonal homolog 1 (ATOH1) by inhibition of the natural antisense transcript to ATOH1
HUE054179T2 (en) 2010-06-23 2021-08-30 Curna Inc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
JP5998131B2 (en) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド DISCSLARGEHOMOLOG (DLG) Treatment of DLG-related diseases by inhibition of natural antisense transcripts on DLG1
JP5986998B2 (en) 2010-10-06 2016-09-06 カッパーアールエヌエー，インコーポレイテッド Treatment of NEU4-related diseases by inhibition of natural antisense transcripts to sialidase 4 (NEU4)
JP6049623B2 (en) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA)
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
RU2608493C2 (en) 2010-11-23 2017-01-18 Курна, Инк. Treating diseases, associated with nanog, by inhibition of natural antisense nanog transcript
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
KR101991980B1 (en) 2011-09-06 2019-06-21 큐알엔에이, 인크. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
CN110438125A (en) 2012-03-15 2019-11-12 科纳公司 By inhibiting the natural antisense transcript of brain derived neurotrophic factor (BDNF) to treat BDNF related disease
MX2016012903A (en) 2014-04-01 2016-12-07 Procter & Gamble Method for screening trp channels.
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
KR102422625B1 (en) 2015-10-09 2022-07-20 유니버시티 오브 사우스앰톤 Regulation of gene expression and screening of deregulated protein expression
ES2882500T3 (en) 2015-12-14 2021-12-02 Cold Spring Harbor Laboratory Antisense oligomers for the treatment of Dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2018081189A1 (en) 2016-10-25 2018-05-03 The Procter & Gamble Company Fibrous structures
US10745865B2 (en) 2016-10-25 2020-08-18 The Procter & Gamble Company Creped fibrous structures
AU2018322319B2 (en) 2017-08-25 2021-08-05 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
IL298063A (en) 2020-05-11 2023-01-01 Stoke Therapeutics Inc opa1 antisense oligomers for the treatment of conditions and diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278038B1 (en) * 1992-04-10 2001-08-21 Oregon Health And Science University Mammalian melanocortin receptors and uses
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
FR2724934B1 (en) * 1994-09-26 1997-01-24 Bio Merieux CHIMERIC OLIGONUCLEOTIDE AND ITS USE IN OBTAINING NUCLEIC ACID TRANSCRIPTS
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU742391B2 (en) * 1997-08-20 2002-01-03 Regents Of The University Of California, The Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP1047711B1 (en) * 1998-01-22 2003-08-20 The Regents of the University of California Nucleic acid sequences encoding capsaicin receptors
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
GB9822124D0 (en) * 1998-10-09 1998-12-02 Univ London Ion channels
AU2148000A (en) * 1998-11-13 2000-06-05 Millennium Pharmaceuticals, Inc. Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof
GB9826359D0 (en) 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
GB9827016D0 (en) 1998-12-08 1999-02-03 Merck Sharp & Dohme Receptor protein
AU4237400A (en) 1999-04-15 2000-11-02 Ortho-Mcneil Pharmaceutical, Inc. Dna encoding the human vanilloid receptor vr1
US6482611B1 (en) * 1999-09-23 2002-11-19 Neurogen Corporation Human capsaicin receptor and uses thereof
AU2002331180A1 (en) * 2001-08-27 2003-03-10 Novartis Pharma Gmbh Nogo receptor homologues and their use

Also Published As

Publication number Publication date
WO2002018407A9 (en) 2003-05-15
DE50113568D1 (en) 2008-03-20
WO2002018407A2 (en) 2002-03-07
WO2002018407A3 (en) 2002-10-03
EP1313768B1 (en) 2008-02-06
PL366039A1 (en) 2005-01-24
CA2420656A1 (en) 2003-02-26
US20100316615A1 (en) 2010-12-16
US7662948B2 (en) 2010-02-16
NZ524894A (en) 2005-03-24
MXPA03001627A (en) 2003-06-24
ATE385505T1 (en) 2008-02-15
HUP0301805A3 (en) 2005-12-28
EP1313768A2 (en) 2003-05-28
HUP0301805A2 (en) 2003-08-28
JP2004507263A (en) 2004-03-11
ES2300366T3 (en) 2008-06-16
US20040002473A1 (en) 2004-01-01

Similar Documents

Publication Publication Date Title
AU2001295531A1 (en) Antisense oligonucleotides against vanilloid receptor 1
CA2296535A1 (en) Antisense oligonucleotide inhibition of ras
EP1340765A3 (en) Inverted chimeric and hybrid oligonucleotides
WO1999051731A3 (en) Maize histone deacetylases and their use
DE69835201D1 (en) Neoglycoproteine
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
MXPA03002413A (en) B7-like molecules and uses thereof.
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
HUP9801216A3 (en) Dna molecules, preparation thereof and use thereof in gene therapy
CA2274581A1 (en) Oligonucleotide compositions and methods for the modulation of the expression of b7 protein
AU8881201A (en) Tnf receptor-like molecules and uses thereof
MX9801264A (en) Control of cd44 gene expression for therapeutic use.
WO2002012338A3 (en) Screening method
WO2003106681A3 (en) Antisense oligonucleotides against pim1
GR3034534T3 (en) Novel polymer supports for nucleic acid synthesis
DE60134645D1 (en) AMIDINE DERIVATIVES AS SELECTIVE NMDA RECEPTOR ANTAGONISTS
CA2495298A1 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
WO2004013313A3 (en) Antisense nucleic acids
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
AU2001233957A1 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
GB9711389D0 (en) Bacterial pheromones and uses therefor
WO2005035549A3 (en) Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO2004108898A3 (en) Transfection agents
WO1997044346A2 (en) Specific inhibitors of dna methyltransferase enzyme

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application